ClinicalTrials.gg
Enrolling by invitationNCT07356232PANDORAUpdated Nov 17, 2026

Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease

An interventional study of Partial enteral nutrition - orally consumed formula in Crohn's Disease, Active, sponsored by James Lewis. Enrolling by invitation at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by James Lewis · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now Enrolling by invitationStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Planned enrollment
226th of 528
80 · median 60
Started
2026
with 32 others
No phase
128 of 660
28 open now
Primary completion
2029-04
later than 129 of 162 live
Registered
633rd of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 226th largest by planned enrollment of the 528 interventional ones that give a count, is one of 33 that started in 2026, is one of 128 with no phase, reaches primary completion later than 129 of the 162 other live ones, and was the 633rd registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter non-randomized prospective open label trial of partial enteral nutrition (PEN) among patients with active Crohn's disease (CD) starting standard of care advanced therapy. Our central hypothesis is that combination therapy of PEN and pharmacologic therapy is more efficacious than pharmacologic therapy alone and can be well-tolerated for patients. Participants will choose to either include PEN along with starting their advanced therapy or will choose not to include PEN. 80 participants will be recruited from 15 sites across the United States.

03

Conditions studied

  • Crohn's Disease, Active

Keywords

  • partial enteral nutrition
  • Crohn's disease exclusion diet
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide
  2. A confirmed diagnosis of Crohn's disease
  3. Plan to start one advanced Crohn's Disease therapy (anti-TNF, anti-IL12/IL23, anti-IL23, anti-alpha 4 beta 7, JAK inhibitor).
  4. If taking aminosalyilates, methotrexate or thiopurines, participant must be on a stable does for at least 8 weeks prior to screening. Methotrexate, aminosalicylates and thiopurines are permitted to be continued with the advanced therapy if on stable dose for at least 8 weeks. Methotrexate or thiopurines may be initiated within 1 week of starting the advanced pharmacologic therapy
  5. Active disease defined by at least one of the criteria from group A AND one from group B.

Group A

  1. Short Crohn's Disease Activity Index (sCDAI) score >175, and if taking , dose cannot exceed 30 mg for prednisone or 9 mg for budesonide,
  2. sCDAI \< 175 and on 10- 30 mg of prednisone (or 6-9 mg of budesonide) at a stable dose for 2 weeks. Must have experienced worsening of symptoms with attempts to taper to a lower dose of steroids in 3 months prior to screening.

Group B

  1. Fecal calprotectin at baseline ≥ 300 ug/gr
  2. Active disease seen at colonoscopy within 8 weeks of the screening visit. Active disease requires presence of mucosal breaks including either diffuse scattered erosions or at least one ulcer (>5mm diameter)
  3. Active disease on cross-sectional imaging (CT scan, MRI or ultrasound) within 8 weeks of the screening visit (evidence of acute inflammation, such as ulceration or bowel wall thickening with restricted diffusion)

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or breast feeding
  2. Presence of an ostomy
  3. Previous total colectomy
  4. Short gut syndrome from prior surgeries
  5. Consuming parenteral nutrition for more than 350 calories per day in the two weeks prior to screening
  6. Having been on the Crohn's Disease Exclusion Diet (CDED) in the 2 weeks prior to screening
  7. Plan to receive two simultaneously administered advanced therapies
  8. Planning to start a new medication in the same class as the medication currently taking. This does not include a switch from Ustekinumab to anti-IL23 drugs.
  9. Impending need for CD surgery per investigator
  10. Symptomatic stricture or stricture inducing bowel dilation (>3cm) as per local investigator.
  11. >4 very soft or liquid bowel movements per day when feeling well
  12. Diabetes mellitus requiring therapy with medication
  13. Known allergy to any ingredient in the Kate Farms formula.
  14. Unable to complete online surveys
  15. Unable to receive shipments of PEN formula.
  16. Starting a new medication for Crohn's disease other than in the 8 weeks prior to the screening visit
  17. Has not consumed food in the last 6 days prior to screening
  18. Starting an accelerated (non-FDA approved) dose of advanced therapy
  19. At time of screening, participant is taking both Prednisone and Budesonide
  20. Untreated C. difficile infection with the last 8 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Partial enteral nutrition

    Participants will consume Kate Farms Peptide 1.5 for 60% of their calories for 8 weeks

    Dietary Supplement: Partial enteral nutrition - orally consumed formula

  • No intervention
    No partial enteral nutrition

Interventions

  • Dietary supplementPartial enteral nutrition - orally consumed formula

    Participants will consume Kate Farms Peptide 1.5 for approximately 60% of their calories while following the Crohn's Disease Exclusion Diet.

06

What researchers measure

Primary outcomes

  1. Rate of steroid-free remission following 8 weeks of pharmacologic therapy

    Steroid-free clinical remission at Visit 5 (week 8) of pharmacologic therapy initiation will be defined as a short Crohn's Disease Activity Index (sCDAI) \< 150 points while off steroids. The need to switch therapies, increase or initiate corticosteroids or any other CD drug will be considered as a failure to achieve the primary outcome.

    Time frame: From start of pharmacologic therapy to 8 weeks.

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Apr 2029, 29 months after the start.

Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 29 months is below that.

Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 21, 2026
StartActual
Nov 3, 2026was Sep 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Oct 27, 2026
Sites
6 sites added
Show 6 added (6 United States)
  • Cedars-Sinai Medical Center · Beverly Hills, United States
  • University of North Carolina · Chapel Hill, United States
  • University of Texas at Austin, Dell Med · Austin, United States
  • Rutgers University · New Brunswick, United States
  • Yale University · New Haven, United States
  • Univeristy of Alabama at Birmingham · Birmingham, United States
across 4 updates, Oct 27, 2026 – Nov 17, 2026
Start date
Sep 2026→Nov 2026
Oct 27, 2026
Contact
No study contact listed any more: removed R•••@pennmedicine.upenn.edu · •••3160
Oct 27, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Pennsylvania · Philadelphia, United StatesContact removed (no phone or email listed)Contact removed n•••@pennmedicine.upenn.eduContact removed (no phone or email listed)
Oct 27, 2026
Sponsor
University of Pennsylvania→James Lewis
Oct 27, 2026
Show all 4 updates
  1. Nov 17, 2026
    1 site added
    Show site
    • Univeristy of Alabama at Birmingham · Birmingham, United States
  2. Nov 12, 2026
    1 site added
    Show site
    • Yale University · New Haven, United States
    + 2 other changes: verification date and date precision
  3. Nov 3, 2026
    1 site added
    Show site
    • Rutgers University · New Brunswick, United States
  4. Oct 27, 2026
    Not yet recruiting→Enrolling by invitation
    3 sites added
    Show 3 added (3 United States)
    • Cedars-Sinai Medical Center · Beverly Hills, United States
    • University of North Carolina · Chapel Hill, United States
    • University of Texas at Austin, Dell Med · Austin, United States
    Start date Sep 2026→Nov 2026
    Sponsor University of Pennsylvania→James Lewis
    Contact No study contact listed any more: removed R•••@pennmedicine.upenn.edu · •••3160
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Pennsylvania · Philadelphia, United StatesContact removed (no phone or email listed)Contact removed n•••@pennmedicine.upenn.eduContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07356232
Lead sponsor
James Lewis
Responsible party
James Lewis (Professor of Medicine and Epidemiology, University of Pennsylvania) — Sponsor-investigator
First posted
Jan 21, 2026
Start date
Nov 3, 2026
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

James Lewis, MD, MSCE
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion